My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Nektar Therapeutics - Common Stock (NQ:NKTR)

59.58 +2.90 (+5.12%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

68 Biggest Movers From Yesterday ↗

April 19, 2022

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide ↗

April 18, 2022

U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.

Via Benzinga

Expert Ratings for Nektar Therapeutics ↗

April 18, 2022

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why is Nektar Therapeutics (NKTR) Stock Down Today? ↗

March 14, 2022

Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 18, 2022

Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical...

Via Benzinga

Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views ↗

April 18, 2022

U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

April 18, 2022

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....

Via Benzinga

Why Nektar Shares Are Down Almost 35% ↗

April 18, 2022

Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points ↗

April 18, 2022

U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022 ↗

April 18, 2022

Upgrades

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More ↗

April 18, 2022

Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 18, 2022

Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion....

Via Benzinga

Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program ↗

April 18, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 14, 2022

Gainers

Via Benzinga

Best Performers Since 3/14 Pivot ↗

March 22, 2022

Early last week, the US equity market pivoted, gaining 1%+ for four consecutive days between last Tuesday and last Friday. Sentiment has shifted amongst the investing community for the time being.

Via Talk Markets

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗

March 20, 2022

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...

Via Benzinga

What 4 Analyst Ratings Have To Say About Nektar Therapeutics ↗

March 15, 2022

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Where Nektar Therapeutics Stands With Analysts ↗

March 15, 2022

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

March 15, 2022

Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading.

Via Benzinga

Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher ↗

March 14, 2022

U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow...

Via Benzinga

96 Biggest Movers From Yesterday ↗

March 15, 2022

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 14, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion....

Via Benzinga

Knightscope News: Why Is KSCP Stock Up Today? ↗

March 14, 2022

Knightscope (KSCP) stock is on the move Monday following news that the company signed onto a new real estate development project.

Via InvestorPlace

Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points ↗

March 14, 2022

The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday. The Dow traded up 0.61% to 33,143.88 while the NASDAQ fell 1.13% to 12,698.26....

Via Benzinga

Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit ↗

March 14, 2022

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Crude Oil Dips 8% ↗

March 14, 2022

U.S. stocks opened on a strong note this morning, with the Dow Jones gaining 300 points on Monday. Following the market opening Monday, the Dow traded up 0.99% to 33,269.95 while...

Via Benzinga

50 Stocks Moving In Monday's Mid-Day Session ↗

March 14, 2022

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,...

Via Benzinga

Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops ↗

March 14, 2022

Sentiment was low heading into the study and analysts aren't hopeful for other tests.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022 ↗

March 14, 2022

Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.